Posology: Adults: The maximum daily recommended dose of Zemiglo is 50 mg once daily. If a dose is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
When used in combination with a sulfonylurea or insulin, a lower dose of the sulfonylurea or insulin may be required to reduce the risk of hypoglycaemia (see Precautions).
Additional information on special populations: Renal impairment: For patients with renal impairment, no dose adjustment is required (see Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions).
Hepatic Impairment: No dose adjustment is necessary for patients with mild or moderate hepatic impairment. There is no clinical experience in patients with severe hepatic impairment. Therefore, caution should be exercised in this population (see Pharmacology: Pharmacokinetics under Actions).
Elderly: The efficacy and safety of gemigliptin were not different between young and elderly patients. However, Zemiglo should be used with caution in elderly patient because physiological functions including liver and kidney are usually decreased in this population (see Pharmacology: Pharmacodynamics under Actions).
Pediatric Population: Safety and effectiveness in children and adolescents less than 18 years of age have not been established.
Method of Administration: Zemiglo can be taken with or without food.